Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

24-10-2018

NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Carnival Corporation (NYSE:CCL), Cadence Design Systems, Inc. (NASDAQ:CDNS), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

SPPI DOWNLOAD: https://MarketSourceResearch.com/register/?so=SPPI
CCL DOWNLOAD: https://MarketSourceResearch.com/register/?so=CCL
CDNS DOWNLOAD: https://MarketSourceResearch.com/register/?so=CDNS
TNDM DOWNLOAD: https://MarketSourceResearch.com/register/?so=TNDM
RIGL DOWNLOAD: https://MarketSourceResearch.com/register/?so=RIGL
REGN DOWNLOAD: https://MarketSourceResearch.com/register/?so=REGN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Carnival Corporation (NYSE:CCL), Cadence Design Systems, Inc. (NASDAQ:CDNS), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 22nd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

SPECTRUM PHARMACEUTICALS, INC. (SPPI) REPORT OVERVIEW

Spectrum Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Spectrum Pharmaceuticals reported revenue of $24.17MM vs $34.30MM (down 29.54%) and analysts estimated basic earnings per share $0.13 vs -$0.27. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Spectrum Pharmaceuticals reported revenue of $128.37MM vs $146.44MM (down 12.34%) and analysts estimated basic earnings per share -$1.07 vs -$0.96. Analysts expect earnings to be released on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is -$0.75 and is expected to report on March 5th, 2019.

To read the full Spectrum Pharmaceuticals, Inc. (SPPI) report, download it here: https://MarketSourceResearch.com/register/?so=SPPI

-----------------------------------------

CARNIVAL CORPORATION (CCL) REPORT OVERVIEW

Carnival's Recent Financial Performance

For the three months ended August 31st, 2018 vs August 31st, 2017, Carnival reported revenue of $5,836.00MM vs $5,515.00MM (up 5.82%) and analysts estimated basic earnings per share $2.42 vs $1.84 (up 31.52%). For the twelve months ended November 30th, 2017 vs November 30th, 2016, Carnival reported revenue of $17,510.00MM vs $16,389.00MM (up 6.84%) and analysts estimated basic earnings per share $3.61 vs $3.73 (down 3.22%). Analysts expect earnings to be released on December 18th, 2018. The report will be for the fiscal period ending November 30th, 2018. Reported EPS for the same quarter last year was $0.63. The estimated EPS forecast for the next fiscal year is $4.70 and is expected to report on December 18th, 2018.

To read the full Carnival Corporation (CCL) report, download it here: https://MarketSourceResearch.com/register/?so=CCL

-----------------------------------------

CADENCE DESIGN SYSTEMS, INC. (CDNS) REPORT OVERVIEW

Cadence Design's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Cadence Design reported revenue of $518.39MM vs $479.00MM (up 8.22%) and analysts estimated basic earnings per share $0.27 vs $0.25 (up 8.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cadence Design reported revenue of $1,943.03MM vs $1,816.08MM (up 6.99%) and analysts estimated basic earnings per share $0.75 vs $0.71 (up 5.63%). Analysts expect earnings to be released on January 30th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.29. The estimated EPS forecast for the next fiscal year is $1.15 and is expected to report on January 30th, 2019.

To read the full Cadence Design Systems, Inc. (CDNS) report, download it here: https://MarketSourceResearch.com/register/?so=CDNS

-----------------------------------------

TANDEM DIABETES CARE, INC. (TNDM) REPORT OVERVIEW

Tandem Diabetes Care's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Tandem Diabetes Care reported revenue of $34.13MM vs $21.33MM (up 60.01%) and basic earnings per share -$1.17 vs -$4.36. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tandem Diabetes Care reported revenue of $107.60MM vs $84.25MM (up 27.72%) and analysts estimated basic earnings per share -$12.87 vs -$27.30. Analysts expect earnings to be released on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$3.09. The estimated EPS forecast for the next fiscal year is -$0.76 and is expected to report on March 7th, 2019.

To read the full Tandem Diabetes Care, Inc. (TNDM) report, download it here: https://MarketSourceResearch.com/register/?so=TNDM

-----------------------------------------

RIGEL PHARMACEUTICALS, INC. (RIGL) REPORT OVERVIEW

Rigel Pharmaceuticals' Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Rigel Pharmaceuticals reported revenue of $4.48MM vs $20.38MM (down 78.00%) and analysts estimated basic earnings per share -$0.62 vs -$0.73. Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.54 and is expected to report on March 5th, 2019.

To read the full Rigel Pharmaceuticals, Inc. (RIGL) report, download it here: https://MarketSourceResearch.com/register/?so=RIGL

-----------------------------------------

REGENERON PHARMACEUTICALS, INC. (REGN) REPORT OVERVIEW

Regeneron Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Regeneron Pharmaceuticals reported revenue of $1,608.02MM vs $1,470.12MM (up 9.38%) and analysts estimated basic earnings per share $5.12 vs $3.66 (up 39.89%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Regeneron Pharmaceuticals reported revenue of $5,872.23MM vs $4,860.43MM (up 20.82%) and analysts estimated basic earnings per share $11.27 vs $8.55 (up 31.81%). Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $3.32. The estimated EPS forecast for the next fiscal year is $18.64 and is expected to report on February 14th, 2019.

To read the full Regeneron Pharmaceuticals, Inc. (REGN) report, download it here: https://MarketSourceResearch.com/register/?so=REGN

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that’s ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Latest news
Related news
Related shares
Rigel Pharmaceuticals Inc
VOL 1,340,703
2.020 USD
0.00 / 0.00 %

Cadence Design Systems Inc
VOL 713,057
45.48 USD
0.00 / 0.00 %

Regeneron Pharmaceuticals Inc
VOL 655,400
401.21 USD
0.00 / 0.00 %

Spectrum Pharmaceuticals Inc
VOL 629,510
10.43 USD
0.00 / 0.00 %

Tandem Diabetes Care Inc
VOL 507,003
42.17 USD
0.00 / 0.00 %

Carnival Corporation
VOL 822,939
54.27 USD
-0.25 / -0.46 %